Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ERCC5 | P28715 | 2/20 | 0.46 |
| ▸ | FEN1 | P39748 | 2/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | PYGL | P06737 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17295199 | 0.84 | ERCC5 (0.51) | HPGDNPC1RAB9AERCC5FEN1 | |
| SCHEMBL9423079 | 0.82 | HPGD (0.49) | HPGDNPC1RAB9AERCC5FEN1 | |
| SCHEMBL8492279 | 0.82 | ERCC5 (0.67) | HPGDERCC5FEN1ALDH1A1MAPK1 | |
| SCHEMBL18451321 | 0.80 | HPGD (0.50) | HPGDNPC1RAB9AERCC5FEN1 | |
| SCHEMBL3412192 | 0.80 | TDP1 (0.47) | HPGDNPC1RAB9AP2RX7ALDH1A1 | |
| SCHEMBL30228141 | 0.80 | TDP1 (0.47) | HPGDNPC1RAB9AP2RX7ALDH1A1 | |
| SCHEMBL473969 | 0.80 | HPGD (0.53) | HPGDNPC1RAB9AP2RX7PYGL | |
| SCHEMBL30231714 | 0.80 | HPGD (0.53) | HPGDNPC1RAB9AP2RX7PYGL | |
| SCHEMBL8967743 | 0.79 | HPGD (0.46) | HPGDNPC1RAB9AP2RX7PYGL | |
| SCHEMBL8493470 | 0.79 | ALDH1A1 (0.48) | HPGDRAB9AERCC5FEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-03 | — | — | US | disclosed |
| EP-1741702-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | MAPK1, NOS1, NOS2 | HPGD 55/4885NPC1 1526/4885RAB9A 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.